Skip to main content
padlock icon - secure page this page is secure

Open Access Using Pittsburgh Compound B for PET Imaging Across The Alzheimer's Disease Spectrum

Download Article:
 Download
(PDF 459.4 kb)
 
Use of biomarkers in the detection of early and preclinical Alzheimer's disease (AD) has become of central importance for the diagnosis of AD, mild cognitive impairment (MCI), and preclinical AD following publication of the NIA-Alzheimer's Association revised criteria for diagnosis across the spectrum of AD pathogenesis. The use of in vivo PET amyloid imaging agents, such as Pi ttsburgh Compound- B , allows early detection of AD pathological processes and subsequent neurodegeneration. Imaging with PiB provides early, or perhaps even preclinical, detection of disease and accurately distinguishes AD from dementias of other etiologies in which the diagnostic distinction is difficult to make clinically. From a research perspective, utilizing amyloid imaging agents allows us to study relationships between amyloid pathology and changes in cognition, brain structure, and function across the continuum from normal aging to MCI to AD. The present review focuses on use of PiB-PET across the spectrum of AD pathogenesis.

33 References.

No Supplementary Data.
No Article Media
No Metrics

Keywords: ALZHEIMER'S DISEASE; AMYLOID; NEUROIMAGING; PITTSBURGH COMPOUND B

Document Type: Research Article

Publication date: May 1, 2016

More about this publication?
  • Technology and Innovation, edited and published by the National Academy of Inventors, is a forum for presenting information encompassing the entire field of applied sciences, with a focus on transformative technology and academic innovation. Regular features of T&I include commentaries contributed by the United States Patent and Trademark Office (USPTO) and in-depth profiles of Fellows of the National Academy of Inventors in every issue.

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more